Aduhelm Ancillary Costs to Push Medicare Spending Even Higher

A new cost analysis taking into account spending on ancillary health services suggests that prior cost analyses underestimated the anticipated costs of aducanumab.
Medscape Medical News

source https://www.medscape.com/viewarticle/966710?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

Heart Failure Care Outside of ICU Can Lower Cost